[March 27, 2015]

InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting

InVivo Therapeutics Holdings Corp. (NVIV) today announced the company is exhibiting at the 66^th Southern Neurosurgical Society (SNS) Annual Meeting being held in Naples, Florida on March 25-28, 2015. Tom Ulich, MD, InVivo's Chief Scientific Officer, and Lorianne Masuoka, MD, InVivo's Chief Medical Officer, are presenting intraoperative videos from the company's ongoing Investigational Device Exemption (IDE) pilot study, which has enrolled two subjects thus far. The videos provide an update to the neurosurgical community on the company's investigational Neuro-Spinal Scaffold novel implantation techniques, which until InVivo's pilot study, had never been performed in patients with spinal cord injury.

Dr. Dom Coric, Chief of Neurosurgery at Carolinas Medical Center in Charlotte, NC, is the current President of the Southern Neurological Society. Carolinas Medical Center is the clinical site that enrolled the second subject in the company's pilot trial.

Lorianne Masuoka, MD, said, "In his Presidential Address today, Dr. Coric highlighted the clinical study of the Neuro-Spinal Scaffold as a recent research effort and shared a video of Neuro-Spinal Scaffold implantation in the second subject of our clinical trial. It was gratifying to see a large neurosurgical audience exposed to our investigational product and implantation procedure."

Mark Perrin, InVivo's CEO and Chairman, said, "As we continue to progress our Neuro-Spinal Scaffold pilot trial, it is important to continually build our relationships with the neurosurgical community. The implantation procedure of our investigational product is novel, and having the ability to show videos of the technique to a neurosurgical audience is extremely beneficial."

On March 26, the company announced the reopening of enrollment for subjects three through five for anticipated completion of its pilot trial in patients with acute thoracic spinal ord injury. The trial has been approved by the FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold.

About the Neuro-Spinal Scaffold

Following an acute spinal cord injury, the biodegradable Neuro-Spinal Scaffold is surgically implanted at the epicenter of the wound and acts as a physical substrate for nerve sprouting. Appositional healing to spare spinal cord tissue, decreased post-traumatic cyst formation, and decreased spinal cord tissue pressure have been demonstrated in preclinical models of spinal cord contusion injury. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and is currently being studied in an IDE pilot study for the treatment of complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple (News - Alert) Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect" and similar expressions, and include statements regarding the anticipated completion of the scaffold pilot study . Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company's ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company's ability to obtain FDA approval to commercialize its products; the company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company's products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company's Annual Report on Form 10-K for the year ended December 31, 2014, and its other filings with the SEC (News - Alert), including the company's Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

[ Back To TMCnet.com's Homepage ]